These studies together suggest that NF-κB functions as a negative regulator of muscle regeneration, and that NF-κB overactivation contributes to muscle wasting during cancer cachexia or aging, highlighting NF-κB as a potentially druggable target to ameliorate muscle wasting in these two conditions. The gene discussed is NFKB1; the disease is cancer.